The ROS proto-oncogene 1 (ROS1) gene rearrangement has been identified in 1% to 2% of non-small cell lung cancer (NSCLC) patients.[1] To date, the known fusion partners of ROS1 include CD74, SDC4, and EZR.[2] With the increasing application of next-generation sequencing (NGS), more rare fusion genes have been identified, and these complex fusions and mutations may impact the effectiveness of drug therapy. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.